Seroatlas · Human Serome Atlas

SP140L

Nuclear body protein SP140-like protein

Also known as: SP14L_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9H930
Gene
SP140L
Ensembl
ENSG00000185404
Chromosome
2
Canonical length
580 aa
Protein class
Predicted intracellular proteins, Transcription factors
Subcellular location
Nucleoplasm

OverviewNCBI Gene

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

580 residues, UniProt reviewed canonical sequence.

>Q9H930|SP140L
     1  MAGGGSDLST RGLNGGVSQV ANEMNHLPAH SQSLQRLFTE DQDVDEGLVY DTVFKHFKRH
    61  KLEISNAIKK TFPFLEGLRD RELITNKMFE DSEDSCRNLV PVQRVVYNVL SELEKTFNLS
   121  VLEALFSEVN MQEYPDLIHI YKSFKNAIQD KLSFQESDRK EREERPDIKL SLKQGEVPES
   181  PEARKESDQA CGKMDTVDIA NNSTLGKPKR KRRKKKGHGW SRMGTRTQKN NQQNDNSKAD
   241  GQLVSSEKKA NMNLKDLSKI RGRKRGKPGT HFTQSDRAPQ KRVRSRASRK HKDETVDFQA
   301  PLLPVTCGGV KGILHKEKLE QGTLAKCIQT EDGKWFTPME FEIKGGYARS KNWRLSVRCG
   361  GWPLRRLMEE GSLPNPPRIY YRNKKRILKS QNNSSVDPCM RNLDECEVCR DGGELFCCDT
   421  CSRVFHEDCH IPPVESEKTP WNCIFCRMKE SPGSQQCCQE SEVLERQMCP EEQLKCEFLL
   481  LKVYCCSESS FFAKIPYYYY IREACQGLKE PMWLDKIKKR LNEHGYPQVE GFVQDMRLIF
   541  QNHRASYKYK DFGQMGLRLE AEFEKDFKEV FAIQETNGNS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SP140L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.43
Highest tissue expression
25 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 25 nTPM
  • lymph node: 23 nTPM
  • tonsil: 19 nTPM
  • appendix: 18 nTPM
  • small intestine: 16 nTPM
  • liver: 15 nTPM

Single-cell type

  • b-cells: 158 nCPM
  • t-cells: 81 nCPM
  • nk-cells: 77 nCPM
  • microglia: 73 nCPM
  • urothelial cells: 63 nCPM
  • hematopoietic stem cells: 53 nCPM

Immune cell

  • naive B-cell: 33 nTPM
  • memory B-cell: 30 nTPM
  • NK-cell: 23 nTPM
  • basophil: 21 nTPM
  • naive CD4 T-cell: 20 nTPM
  • MAIT T-cell: 19 nTPM

Brain region

  • medulla oblongata: 9.5 nTPM
  • thalamus: 9 nTPM
  • white matter: 8.9 nTPM
  • choroid plexus: 8.5 nTPM
  • pons: 8.5 nTPM
  • cerebral cortex: 7.4 nTPM

ReferencesPubMed · IEDB

Publications for SP140L from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.8
gnomAD pLI
0
gnomAD missense Z
-0.09
DepMap mean gene effect
0.07
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SP140L as an antibody target. Whether an autoantibody or antibody against SP140L could matter depends on whether native SP140L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SP140L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SP140L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SP140L. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...